Clinical Trial Network For Antibiotics Included In President’s FY 2016 Budget
This article was originally published in The Pink Sheet Daily
Executive Summary
$1.2 billion budget request to combat antibiotic resistance includes $650 million for development of antibacterials; supports development of new approval pathway.
You may also be interested in...
Top US FDA Drug Policy Leader Leaving For White House Detail
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.